Inhibition of the activity of CRM1 has been extensively explored as a therapeutic target to inhibit shuttling nucleocytoplasmic transport in melanoma, thyroid, and other types of cancers [9,11,12,17,19,23,24,26,27,28,29,30,31,32]. The gene discussed is XPO1; the disease is cancer.